Related Experiment Video
Updated: Feb 12, 2026
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Genetic modifiers of severity in sickle cell disease
Alicia K Chang1, Carly C Ginter Summarell1, Parendi T Birdie1
1Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA.
Insights
Sickle cell disease (SCD) shows significant clinical variation. Identifying genetic factors is key to understanding and treating SCD complications, improving patient outcomes.
Area of Science:
- Genetics
- Hematology
- Molecular Biology
Background:
- Sickle cell disease (SCD) is a prevalent global blood disorder.
- SCD exhibits considerable clinical heterogeneity, with varying severity and complications even among genetically identical individuals.
- Known factors like fetal hemoglobin (HbF) levels and certain genetic polymorphisms do not fully explain this variability.
Purpose of the Study:
- To investigate the genetic underpinnings of clinical heterogeneity in sickle cell disease.
- To identify novel genetic variants associated with specific SCD complications.
- To improve the prediction of disease course and complications in SCD patients.
Main Methods:
- Review of existing literature on genetic factors influencing SCD.
- Analysis of data from large-scale genetic studies, including whole genome sequencing.
- Integration of global sample collections to enhance statistical power.
Main Results:
- Previous studies have identified some genetic associations, but many require validation.
- Current known factors do not account for the full spectrum of SCD clinical presentations.
- Advancements in sequencing technologies and data aggregation are crucial for future discoveries.
Conclusions:
- Further research is needed to fully elucidate the genetic basis of SCD heterogeneity.
- Identifying more genetic variants will enable better prediction of complications.
- This knowledge holds promise for developing targeted therapies for sickle cell disease.
Abstract:
Sickle cell disease (SCD) is one of the most common single disease disorders world-wide. It is remarkable for its clinical heterogeneity, even among individuals with identical genotypes. Some individuals experience morbidity and mortality in early childhood, while others have a relatively mild course, and normal or near normal life expectancy. Many clinical complications are associated with SCD; most notably frequent pain episodes, stroke, acute chest syndrome, avascular necrosis, nephropathy, retinopathy and pulmonary hypertension. While the effects of higher fetal hemoglobin (HbF) levels, UGTA1A polymorphisms, alpha-thalassemia and G6PD deficiency on SCD has been extensively studied, these variables do not explain all of the clinical heterogeneity of SCD. It is not known why some patients develop certain complications, and it is difficult to predict which complications a particular patient will experience. Much work has been done to identify genetic variants associated with these disease complications; many associations remain unvalidated. As the field continues to move beyond small sample collections and candidate gene approaches into whole genome sequencing and merging of samples from all over the world, we will identify more genetic variants associated with development of specific SCD related complications, and hopefully leverage this knowledge into targeted therapies.
Related Concept Videos
00:49What is Genetic Engineering?
02:16Genetics of Speciation
01:25What is Population Genetics?
02:59Animal Mitochondrial Genetics
02:18Types of Genetic Transfer Between Organisms
01:21EPS and iPS Cells in Disease Research